Cancer medicine built for patients: stronger, simpler, and safer.
DUO is The New Chemo.
Duo Oncology is developing tumor-activated prodrug combinations designed to transform toxic multi-agent chemotherapy regimens with single medicines that concentrate therapeutic activity in tumors while limiting healthy-tissue exposure.
Duo's lead clinical-stage product, DUO-207, is designed to replace gemcitabine plus paclitaxel with a single-infusion, tumor-metabolized prodrug built to serve as a next-generation chemotherapy backbone for the KRAS inhibitor era.
Company Snapshot
Clinical-stage prodrug company upgrading entire solid-tumor chemotherapy regimens.
Proprietary tumor-activated chemistry supported by peer-reviewed publications and complete GLP toxicology studies.
Lead product entering an adaptive Phase 1b/2 trial with enrollment across pancreatic, lung, and breast cancers.
Experienced oncology leadership backed by BeOne Medicines, venture investors, NIH National Cancer Institute and Frederick National Laboratory.
Problem to Solution
Multi-agent chemotherapy remains the foundation of cancer care. Yet today’s regimens are toxic, complicated, and costly. A better backbone would benefit:
Patients and Caregivers: Fewer and faster infusions, better quality of life, and less time feeling sick from treatment.
Hospitals and Clinics: Simpler administration, fewer missed treatments, and a more usable backbone for modern combinations.
Payers and Pharma: Potential for safer standard of care with attractive economics supported by low cost of goods.
Lead Product DUO-207
DUO-207 combines gemcitabine and paclitaxel (GEM + PTX) into a single infusion, tumor-activated prodrug designed to strengthen tumor pharmacology, simplify treatment, and lower systemic exposure.
KRASi momentum makes the backbone matter: daraxonrasib and other KRAS inhibitors have renewed focus on combinations built around GEM + PTX.
DUO-207 is built to be the new chemo: a next-generation GEM + PTX backbone designed to be safer for patients, simpler for clinics, and highly active in tumors.
Robust validation data: DUO-207’s actives have approximately 10-14× longer half-lives in tumor than in blood, beating standard GEM + PTX in multiple models.